News from glaxosmithkline plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 15, 2020, 03:00 ET GSK highlights scientific advances across its growing oncology portfolio at ESMO Virtual Congress 2020

GlaxoSmithKline plc will present new data at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, underscoring its...


Jul 14, 2020, 17:46 ET GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in ...


May 27, 2020, 09:00 ET DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK's investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma

GlaxoSmithKline (GSK) plc today announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme, which...


May 20, 2020, 09:00 ET GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020

As part of its ongoing work to advance potentially transformational medicines, GlaxoSmithKline plc will present new data at the upcoming 2020...


Apr 29, 2020, 16:13 ET FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) approved the company's supplemental New Drug...


Feb 27, 2020, 04:00 ET European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company's Type II Variation (T2V) for Zejula (niraparib) as...


Feb 24, 2020, 09:00 ET U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

GlaxoSmithKline plc today announced that the U.S. Food and Drug Administration (FDA) accepted the company's submission of a supplemental New Drug...


Feb 03, 2020, 04:00 ET GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma

GlaxoSmithKline plc today announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for belantamab...


Jan 21, 2020, 09:00 ET US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) granted a priority review for the company's Biologics License ...


Dec 16, 2019, 18:36 ET Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma

Overall response rate (ORR) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to...


Sep 30, 2019, 09:51 ET GSK presenta nuevos datos que muestran una prometedora actividad antitumoral con GSK3359609, un agonista de los receptores de ICOS, en combinación con pembrolizumab en el carcinoma de células escamosas de cabeza y cuello (HNSCC)

GlaxoSmithKline plc (LSE/NYSE: GSK) anunció hoy que el fármaco GSK3359609, un anticuerpo agonista de los coestimuladores inducibles de células T...


Sep 30, 2019, 09:08 ET 葛兰素史克发布新数据,展示ICOS受体激动剂GSK3359609与派姆单抗结合使用治疗头颈部鳞状细胞癌的抗肿瘤活性

葛兰素史克(GlaxoSmithKline plc) (LSE/NYSE: GSK)今天宣布,旨在选择性增强T细胞功能的诱导性T细胞共刺激分子(ICOS)激动剂抗体GSK3359609在结合使用派姆单抗治疗头颈部鳞状细胞癌(HNSCC)...


Sep 30, 2019, 08:52 ET 葛蘭素史克發佈新數據,展示ICOS受體激動劑GSK3359609與派姆單抗結合使用治療頭頸部鱗狀細胞癌的抗腫瘤活性

葛蘭素史克(GlaxoSmithKline plc) (LSE/NYSE: GSK)今天宣佈,旨在選擇性增強T細胞功能的誘導性T細胞共刺激分子(ICOS)激動劑抗體GSK3359609在結合使用派姆單抗治療頭頸部鱗狀細胞癌(HNSCC)...


Sep 28, 2019, 10:31 ET Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The ...


Sep 28, 2019, 02:53 ET GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively...


Dec 12, 2017, 10:55 ET GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first...


Nov 21, 2016, 07:00 ET GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food...


Jun 02, 2016, 11:00 ET Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD

GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration ...


Feb 22, 2016, 11:06 ET GSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets

GlaxoSmithKline plc (LSE: GSK) today announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and...


Dec 02, 2015, 09:00 ET GSK Announces Nucala® (mepolizumab), Now Available In The Us For Sub-Group Of Patients With Severe Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12 years and...


Nov 09, 2015, 08:00 ET GSK, COPD Foundation and AARC Team Up for #COPDChat, November 9th, 12 pm ET

GlaxoSmithKline plc (LSE: GSK) today announced a tweet chat with the COPD Foundation and American Association for Respiratory Care (AARC) to raise...


Apr 30, 2015, 04:36 ET FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO®...


Jan 26, 2015, 09:17 ET GSK expands its portfolio of medicines in the US for patients with asthma and COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the simultaneous availability of two of its recently approved products for the treatment of...


Aug 26, 2014, 03:52 ET GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application ...


Jul 24, 2014, 01:32 ET FDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Flonase® Allergy Relief...